Oxidation of Drugs during Drug Product Development: Problems and Solutions

Oxidation is the second most common degradation pathway for pharmaceuticals, after hydrolysis. However, in contrast to hydrolysis, oxidation is mechanistically more complex and produces a wider range of degradation products; oxidation is thus harder to control. The propensity of a drug towards oxidation is established during forced degradation studies. However, a more realistic insight into degradation in the solid state can be achieved with accelerated studies of mixtures of drugs and excipients, as the excipients are the most common sources of impurities that have the potential to initiate oxidation of a solid drug product. Based on the results of these studies, critical parameters can be identified and appropriate measures can be taken to avoid the problems that oxidation poses to the quality of a drug product. This article reviews the most common types of oxidation mechanisms, possible sources of reactive oxygen species, and how to minimize the oxidation of a solid drug product based on a well-planned accelerated study.

Automated summary

Oxidation is a common degradation pathway for pharmaceuticals, and it is more complex than hydrolysis, producing a wide range of degradation products. Accelerated studies of drug-excipient mixtures can provide realistic insights into degradation in the solid state, as excipients are the main sources of impurities that can initiate oxidation. Based on the results of these studies, appropriate measures can be taken to minimize the oxidation of solid drug products.